奥美拉唑肠溶胶囊治疗小儿慢性胃炎合并消化性溃疡的临床研究  

Clinical trial of omeprazole enteric-coated capsules in the treatment of children with chronic gastritis and peptic ulcer

作　　者：范三丽 胡海燕 金翠 白静洁 董芳[1] 孙晋芳 秦艳[1] 孟小玲[1] 薛慧琴 FAN San-li;HU Hai-yan;JIN Cui;BAI Jing-jie;DONG Fang;SUN Jin-fang;QIN Yan;MENG Xiao-ling;XUE Hui-qin(Department of Digestive,Children's Hospital Affliated to Shanxi Medical University,Taiyuan 030013,Shanxi Province,China;Cytogenetics Room,Children's Hospital Affliated to Shanxi Medical University,Taiyuan 030013,Shanxi Province,China)

机构地区：[1]山西医科大学附属儿童医院消化科,山西太原030013 [2]山西医科大学附属儿童医院细胞遗传室,山西太原030013

出　　处：《中国临床药理学杂志》2024年第7期973-976,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察奥美拉唑肠溶胶囊对小儿慢性胃炎合并消化性溃疡临床症状及血清炎性因子水平的影响。方法将慢性胃炎合并消化性溃疡患儿按随机数字表法分为试验组和对照组。对照组给予盐酸雷尼替丁片联合阿莫西林、克拉霉素进行三联治疗,试验组给予奥美拉唑肠溶胶囊联合阿莫西林、克拉霉素进行治疗。比较2组患儿的临床疗效、症状缓解时间,以及治疗前后血清胃动素(MOT)、胃泌素(GAS)和炎性因子[白细胞介素(IL)-6、IL-8]水平的变化。结果试验组与对照组各入组48例。治疗后,试验组和对照组的总有效率分别为93.74%(45例/48例)和85.42%(41例/48例),在统计学上差异有统计学意义(P<0.05)。治疗后,试验组和对照组的溃疡疼痛消失时间分别为(1.51±0.26)和(2.08±0.42)d,反酸消失时间分别为(2.29±0.40)和(2.93±0.33)d,烧灼感消失时间分别为(2.37±0.21)和(2.85±0.54)d,住院时间分别为(6.21±1.07)和(6.94±1.25)d,血清MOT水平分别为(298.48±35.15)和(273.58±31.25)pg·mL^(-l),GAS水平分别为(167.28±19.46)和(128.32±18.61)ng·L^(-l),IL-6水平分别为(58.67±5.39)和(76.14±6.63)mg·mL^(-l),IL-8水平分别为(50.08±5.16)和(58.68±5.49)mg·mL^(-l),在统计学上差异均有统计学意义(均P<0.05)。试验组和对照组的总药物不良反应发生率分别为8.33%和12.50%,在统计学上差异无统计学意义(P>0.05)。结论奥美拉唑肠溶胶囊治疗小儿慢性胃炎合并消化性溃疡,能够有效缓解各项临床症状,提高临床疗效,同时降低患儿体内的血清炎性因子水平,改善炎症情况,具有良好的应用效果。Objective To observe the effect of omeprazole enteric-coated capsules on clinical symptoms and serum inflammatory factor levels in children with chronic gastritis and peptic ulcer.Methods Children with chronic gastritis and peptic ulcer were divided into treatment group and control group by random number table method.The control group was given triple therapy of ranitidine hydrochloride tablets,amoxicillin and clarithromycin,while the treatment group was treated with omeprazole enteric-coated capsules combined with amoxicillin and clarithromycin.Clinical efficacy,symptom relief time,and changes in serum motilin(MOT),gastrin(GAS)and inflammatory factors[interlrukin-6(IL-6)and interlrukin-8(IL-8)] were compared between the two groups.Results There were 48 cases in treatment group and 48 cases in control group.After treatment,the total effective rates in treatment group and control group were 93.74%(45 cases/48 cases)and 85.42%(41 cases/48 cases),with significant difference(P<0.05).After treatment,the disappearance time of ulcer induced pain in treatment group and control group were(1.51±0.26)and(2.08±0.42)d;the disappearance time of acid regurgitation were(2.29±0.40)and(2.93±0.33)d;the disappearance time of burning sensation were(2.37±0.21)and(2.85±0.54)d;the length of hospital stay were(6.21±1.07)and(6.94±1.25)d;serum MOT levels were(298.48±35.15)and(273.58±31.25)pg·mL^(-l);serum GAS levels were(167.28±19.46)and(128.32±18.61)ng·L^(-l);IL-6 levels were(58.67±5.39)and(76.14±6.63)mg·mL^(-l);IL-8 levels were(50.08±5.16)and(58.68±5.49)mg·mL^(-l).The above indexes were significantly different between control group and treatment group(all P<0.05).The total incidence of adverse drug reactions in treatment group and control group were 8.33%and 12.50%,with no statistical significance(P>0.05).Conclusion Omeprazole enteric-coated capsules in the treatment of children with chronic gastritis and peptic ulcer can effectively alleviate various clinical symptoms and improve clinical efficacy.At the same time,it

关 键 词：奥美拉唑肠溶胶囊 小儿慢性胃炎 消化性溃疡 血清炎性因子 

分 类 号：R975.6[医药卫生—药品]